112 results
8-K
EX-99.1
SLP
Simulations Plus Inc.
20 May 24
Regulation FD Disclosure
5:00pm
by streamlining the drug development process, creating efficiencies that lead to drug efficacy and safety, higher regulatory approval, improved commercial … it to market 70% of drugs fail in Phase II or Phase III due to safety and efficacy issues
End-to-End Solutions Across the Development Life Cycle
8-K
EX-99.1
SLP
Simulations Plus Inc.
3 Apr 24
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
4:06pm
safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.
Second Quarter 2024 Financial
8-K
EX-99.1
SLP
Simulations Plus Inc.
13 Feb 24
Regulation FD Disclosure
9:15am
by streamlining the drug development process, creating efficiencies that lead to drug efficacy and safety, higher regulatory approval, improved commercial … it to market 70% of drugs fail in Phase II or Phase III due to safety and efficacy issues
End-to-End Solutions Across the Development Life Cycle
8-K
EX-99.2
6ife54g 5hrkysy
3 Jan 24
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
4:06pm
8-K
EX-99.1
83j6j55b wk8vwrldlbn
3 Jan 24
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
4:06pm
8-K
EX-99.1
5bnkko p4md
17 Nov 23
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
5wnc8one0 ar
14 Nov 23
Regulation FD Disclosure
1:00pm
8-K
EX-99.1
qqwvoh5kund9b
7 Jul 23
Regulation FD Disclosure
4:25pm
8-K
EX-99.1
eufz3gk
20 Jun 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-2.1
etf7y9zxxld56d784
20 Jun 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
wkhzmt4 jrxfegd8uj
5 Apr 23
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
4:07pm
8-K
EX-99.1
0wd l2w8yrt8x6nb0
7 Nov 22
Regulation FD Disclosure
1:45pm